Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative precision diagnostic agents that can and will make a difference for individuals – and families, physicians and care givers – touched by devastating conditions like cancer and Alzheimer's disease. Our Company’s core mission is to bring the next generation of precision radiopharmaceutical agents to market so doctors and patients can readily access, and benefit from, cutting-edge diagnostic science.
For patients and physicians, we aspire to provide innovative medical imaging agents to improve patient care for serious diseases. For our shareholders, we aim to deliver superior growth through our focus on our innovative imaging and imaging-related platforms and efficient business processes. For our employees, we provide a culture in which we all focus on the direct contributions our efforts make for the patients we ultimately serve and an innovative development environment for new breakthrough products.
Navidea’s radiopharmaceutical development programs include:
Lymphoseek®, a radiopharmaceutical imaging agent for sentinel lymph node mapping, holds great promise for patients with several different types of solid tumor cancers. Lymphoseek was approved by the U.S. Food and Drug Administration in March 2013 for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.
NAV4694 is a potentially powerful second-generation imaging agent which may aid the diagnosis of Alzheimer's disease allowing patients to seek earlier treatment options.
RIGScanTM CR is a tumor-specific targeting agent that holds great promise for patients with colorectal cancer and potentially other cancers.
Navidea has more than 40 employees worldwide with headquarters in Dublin, Ohio.